65,437 trials
Obesity
Primary: Change in Child Adiposity — -0.55; 0.64 Change in BMI percentile
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
Enteral Nutrition
Primary: Tube Migration — 6 Participants
Dentin Sensitivity · Oral Hygiene
Primary: Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching — 12.00; 12.06 score on a scale — p=0.9141
Unicompartmental Medial Knee Osteoarthritis
Primary: Morphology Assessment Via Correction Angle Assessment — 1.5 Degree
Essential Tremor
Primary: Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo — -6.3; -5.8; -6.7; -7.5 score on a scale
Non-Small Cell Lung Cancer (NSCLC)
Primary: Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) — 16.69; 15.64 months — p=0.6460
Treatment of Bleeding · Prophylaxis of Bleeding · Hemophilia A
Primary: Adverse Events of Special Interest (AESI) Hypersensitivity and Loss of Efficacy Associated With the First 4 Exposure Days (EDs) Leading to Discontinuation — 1 Participants
Thumb Osteoarthritis
Primary: Numeric Pain Rating Scale (NPRS) — 3; 3 units on a scale — p=0.87
Obstructive Sleep Apnea
Primary: Total Length of Desaturation Episodes (ToLDE) Per Patient/Surgical Procedure — 34; 97 minutes
Bradycardia · Heart Failure
Primary: Serious Adverse Device Effect (SADE)-Free Rate After 12 Months — 52 Participants
Height · Cognitive Function · Weight Gain
Primary: Change Mean Percentile Score in Double Trouble — 168.55; 129.46 percent change from baseline — p=0.488445
Suicide · Chronic Pain
Primary: Social Problem-solving Inventory - Patient Report — 8.12; 3.64 score on a scale
Pediatric Obesity · Insulin Resistance
Primary: Palatability of the High Fat Agent. — 13 Participants — p=0.15
Stroke
Primary: Overall Stability Index Measurement — 17.5; 9 units on a scale